Ista falls on Remura miss in dry eye

Ista Pharmaceuticals Inc. (NASDAQ:ISTA) fell $2.23 (31%) to $4.97 on Friday after Remura bromfenac missed the co-primary endpoints of significantly improving one sign and one symptom of dry eye disease at day 42 vs. placebo in the Phase III WEST trial to treat dry eye syndrome. However, Remura did significantly improve one sign and one symptom at 42 days compared to baseline (p<0.0001 for both). The double-blind, U.S. trial enrolled 420 patients. Remura is a topical non-steroidal anti-inflammatory bromfenac ophthalmic solution. ...